AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Imfinzi (durvalumab) — Worldwide product sales by Year
Imfinzi (durvalumab) — Worldwide product sales ($M) ($M)
AstraZeneca Imfinzi (durvalumab) — Worldwide product sales: $6,063M in FY2025, up 28.5% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Imfinzi | 6,063 | 29 | 28 | 3,509 | 35 | 640 | 34 | 38 | 1,239 | 31 | 26 | 675 | (2) | (2)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imfinzi (durvalumab) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,063 | +28.5% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 4,717 | +11.3% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 4,237 | +52.2% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 2,784 | +15.4% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 2,412 | +18.1% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 2,042 | +39.0% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 1,469 | +132.1% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 633 | +3,231.6% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 19 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up imfinzi (durvalumab) — Worldwide product sales
- Imfinzi (durvalumab) — Worldwide YoY actual (%)29.0% · FY2025
- Imfinzi (durvalumab) — Worldwide YoY CER (%)28.0% · FY2025
- Imfinzi (durvalumab) — US product sales ($M)3,509 · FY2025
- Imfinzi (durvalumab) — Emerging Markets product sales ($M)640 · FY2025
- Imfinzi (durvalumab) — Europe product sales ($M)1,239 · FY2025
- Imfinzi (durvalumab) — Established RoW product sales ($M)675 · FY2025
Cite this data
StockData. (2026). AstraZeneca Imfinzi (durvalumab) — Worldwide product sales ($M), annual FY2017–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imfinzi-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.